Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

CvLPRIT: Long-term Reduction in Death/MI With Complete Revascularization

Michael O'Riordan

December 20, 2019

News Daily News

Repeat Target-Lesion PCI: An Option for Public Reporting?

Michael O'Riordan

October 25, 2019

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Opinion Off Script

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

Sahil Parikh, MD

July 29, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News EuroPCR 2019

New Expert Advice on Intracoronary Imaging Urges Shift to Preprocedural Planning

Shelley Wood

May 22, 2019

News Daily News

Staged, Complete PCI Beats Culprit Stenting Out to 5 Years in STEMI Patients

Caitlin E. Cox

May 10, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2019

Shelley Wood

March 29, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

L.A. McKeown

February 26, 2019

News Daily News

NOTION and UK TAVI Report Good Long-term Function of Transcatheter Aortic Valves

L.A. McKeown

February 06, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

Advertisement

CvLPRIT: Long-term Reduction in Death/MI With Complete Revascularization

Repeat Target-Lesion PCI: An Option for Public Reporting?

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

New Expert Advice on Intracoronary Imaging Urges Shift to Preprocedural Planning

Staged, Complete PCI Beats Culprit Stenting Out to 5 Years in STEMI Patients

TCTMD’s Top 10 Most Popular Stories for March 2019

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

NOTION and UK TAVI Report Good Long-term Function of Transcatheter Aortic Valves

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content